Microplate Dx is a Glasgow-based diagnostics company committed to combating antimicrobial resistance (AMR) through rapid and affordable, point-of-care testing. Founded in 2021, originally as a spin-out from the University of Strathclyde, the company has developed the RapidPlateTM platform—a novel diagnostic tool that delivers antibiotic susceptibility results in under 1 hour with gold-standard accuracy, significantly faster than the closet competitor systems which can take days. This technology enables clinicians to prescribe the most effective antibiotic first time, reducing the reliance on antibiotic prescribing guesswork and mitigating the threat of AMR. With support from global investors, Microplate Dx is advancing towards clinical trials and preparing for commercial launch for its first application, urinary tract infections (UTIs) across Europe and the U.S, with the test having widespread applicability across primary/secondary healthcare settings across the world.
